Edge Rewrite
// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2a81ebeb9b5b179

Jump to content

Phenflutermine

From Wikipedia, the free encyclopedia

Phenflutermine
Clinical data
Other namesPhenflutermin; 3-Trifluoromethyl-N-ethyl-α-methylamphetamine; 3-Trifluoromethyl-N-ethylphentermine; N-Ethyl-α,α-dimethyl-3-trifluoromethylphenethylamine; N-Et-α,α-Me-3-TFMPEA; Fenflutermine
ATC code
  • None
Identifiers
  • N-ethyl-2-methyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
Chemical and physical data
FormulaC13H18F3N
Molar mass245.289 g·mol−1
3D model (JSmol)
  • CCNC(C)(C)CC1=CC(C(F)(F)F)=CC=C1
  • InChI=1S/C13H18F3N/c1-4-17-12(2,3)9-10-6-5-7-11(8-10)13(14,15)16/h5-8,17H,4,9H2,1-3H3
  • Key:DRSIPICEAYYBGT-UHFFFAOYSA-N

Phenflutermine, also known as 3-trifluoromethyl-N-ethyl-α-methylamphetamine or as 3-trifluoromethyl-N-ethylphentermine, is a chemical compound of the phenethylamine, amphetamine, and phentermine families.[1] It is the combined or hybrid derivative of the fenfluramine and phentermine, which were used together in the withdrawn combination anorectic fenfluramine/phentermine (Fen-Phen).[1] The compound was first described in the scientific literature by Daniel Trachsel in his book on phenethylamines in 2013.[1] It is not known to have been synthesized, tested, or otherwise described in the literature.[1] However, both fenfluramine and phentermine are known to act as monoamine releasing agents and to have anorectic effects.[2][3]

See also

[edit]

References

[edit]
  1. 1 2 3 4 Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  2. Rothman RB, Baumann MH (2000). "Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects". Drug Development Research. 51 (2): 52–65. doi:10.1002/1098-2299(200010)51:2<52::AID-DDR2>3.0.CO;2-H. ISSN 0272-4391.
  3. Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961.
[edit]